SMi Systems
“SMi is revolutionising the world of molecular science by coupling super-resolution imaging with deep learning to provide unprecedented quantification of single molecules. Our flexible, high-throughput platform delivers fast, accurate and reliable results that reduce project complexity and enable scientists and clinicians to make better informed decisions. With SMi’s platform, discoveries and diagnoses are faster, more […]
Blueberry Therapeutics
Blueberry Therapeutics’ vision is to bring high value, innovative medicines to the market that make a real difference to people’s lives. They have exclusive worldwide access to a nanodelivery platform and apply this technology to enhance delivery of drugs into cells and tissues. Blueberry Therapeutics are using this to create safer, more effective, easier to […]
N4 Pharma
N4 Pharma, established in 2014, is a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle, Nuvec®, has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. N4’s commercial strategy is to advance a pipeline […]
Videregen
Videregen is a leader in the development of personalised, regenerative products to replace, repair and restore organs and tissues. They are a clinical-stage regenerative medicine company using our proprietary technology platform to develop a range of personalised regenerative products targeting chronic, serious and orphan indications. Targeting the growing need for regenerative therapies for serious and […]
CellCentric
CellCentric is a UK based biotechnology company focused on the development of the novel drug CCS1477 for specific cancers. The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes. Over time the company has investigated a wide range of epigenetic-related […]
LUNAC Therapeutics
LUNAC Therapeutics are developing a first-in-class, next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, without the bleeding risk associated with current anticoagulants. Their focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a key role in pathological clot formation (thrombosis) but not in […]
RedX Pharma
Focused on the development of novel targeted medicines to validated anti-cancer and fibrosis targets in areas of unmet need. Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic. The company’s product development strategy has three interrelated components: cancer, fibrosis, and research. We formed a strategic […]
Retrogenix
Retrogenix advances medical research and speeds up drug discovery for its clients by providing a unique service which identifies specific cell surface and secreted protein interactions in human cells. Retrogenix now has research agreements with nineteen of the top twenty global pharmaceutical companies, numerous drug discovery companies and many leading academic and non-for-profit institutions around […]
Peak Proteins
Peak Proteins is a team of outstanding scientists delivering tailored protein supply, X-ray structure determination and protein mass spectrometry services. Proteins are notoriously individual and complex reagents that require careful thought and handling, from design through to purification, to produce high quality, active protein reagents. All their staff have years of drug discovery experience through […]